APPROVED FOR FIRST-LINE USE for adults with prurigo nodularis (PN)

Regardless of disease severity or prior medication use for PN1


DUPIXENT was studied in 2 pivotal trials of adult patients with prurigo nodularis

PRIME and PRIME2 assessed the
effect of DUPIXENT on itch
improvement, as well as its
effect
on PN nodules.1,2

≈3X

as many patients in PRIME had
significantly reduced itch at Week 24
(60% with DUPIXENT
vs 18% with placebo; P<0.001,
primary endpoint)

PRIME2

37% of DUPIXENT patients achieved a meaningful
response at Week 12 vs 22% with placebo; P=0.022
(primary endpoint). At Week 24, 58% of DUPIXENT
patients achieved significant itch relief vs 20% with
placebo; P<0.001 (secondary endpoint)1,2

≈2.5X

as many patients in PRIME achieved
significant nodule clearance
(IGA PN-S 0 or 1) at Week 24
(48% with DUPIXENT vs 18% with
P<0.001, secondary endpoint)

PRIME2

45% of DUPIXENT patients similarly achieved
significant nodule clearance (IGA PN-S 0 or 1) at
Week 24 vs 16% with placebo; P<0.001
(secondary endpoint)1,2

IGA PN-S, Investigator’s Global
Assessment PN-Stage.

Extensive Real-World Experience

 

In the us,
studied in 17  pivotal trials
across 5indications1

Globally,
≈800,000

patients on
DUPIXENT therapy
worldwide
across 5 indications3,c,d

patients on
DUPIXENT therapy

worldwide
across 5 indications3,c,d

AD, atopic dermatitis.

aIQVIA NBRx data as of March 2024.

bFDA approved for uncontrolled moderate-to-severe AD since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for infants to preschoolers (aged 6 months to 5 years).

cThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.

d≈493,000 US patients (new adult and pediatric patients 6+ months of age with uncontrolled moderate-to-severe AD) have filled at least 1 DUPIXENT prescription based on IQVIA National Source of Business (NSOB) data as of [March 2024].

DUPIXENT HAS A DEMONSTRATED
SAFETY PROFILE1

Most common adverse reactions in adult patients with prurigo nodularis (incidence ≥2%) are
nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea

The First and Only Therapy to Target IL‑4Rα, Thereby
SPECIFICALLY Inhibiting IL‑4 and IL‑13 Signaling1,4

The mechanism of dupilumab action has not been definitively established


Other attributes

NOT AN IMMUNOSUPPRESSANT
OR A STEROID1

NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING

according to the Prescribing Information1

NO KNOWN DRUG‑TO‑DRUG
INTERACTIONS1

  • Not metabolized through the liver or
    excreted through the kidneys

NO boxed warning1

Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.

Select Important Safety Information

Warnings and Precautions

  • Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions,
    angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically
    significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT

Discover how DUPIXENT inhibits IL-4
and IL-13 signaling

APPROVED FOR FIRST-LINE USE FOR ADULTS WITH
PRURIGO NODULARIS (PN)

Help appropriate patients benefit from DUPIXENT

Extensive Real-World
Experience ACROSS DUPIXENT

In the us, studied in 17 pivotal trials across 5 indications2

Globally,
≈800,000

patients on DUPIXENT
therapy across 5
indications3,a

aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.

DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

DUPIXENT MyWay
ENROLLMENT FORMS

English Enrollment Form
Spanish Enrollment Form